The Hamilton Watch Company is a Swiss manufacturer of wristwatches based in Bienne, Switzerland. The Hamilton Watch Company had its genesis as an American watch design and manufacturing company, which incorporated in 1892 and produced its first watch in 1893. After its formation, the Hamilton Watch Company went on to manufacture and market pocket watches and wristwatches, ending American manufacture in 1969. Through a series of mergers and acquisitions, the Hamilton Watch Company became a diversified conglomerate itself and was subsequently integrated into the Swatch Group. Today the brand is one of more than twenty watch brands belonging to the Swatch Group, the world's largest watch manufacturer and marketer.
OBJECTIVES:To perform an updated systematic review and meta-analysis of the efficacy and safety of intensive (INT) vs. conventional (CONV) blood glucose (BG) targets for critically ill adults on insulin infusions. DATA SOURCES:We conducted a comprehensive search of Embase and OVID Medline databases from inception to October 16, 2023. We manually excluded studies published before 2000 due to potential lack of relevance as glycemic control in the ICU was not routinely practiced before 2000. STUDY SELECTION:We included randomized controlled trials (RCTs) evaluating adult, critically ill patients on insulin infusions comparing INT vs. CONV targets for efficacy and safety outcomes. DATA EXTRACTION:Data were screened and extracted with accuracy confirmed by a second reviewer. Study methodological characteristics, patient population, interventions, and outcome data were recorded. Studies without numerical outcomes were summarized as text statements. DATA SYNTHESIS:Forty-five RCTs were included involving 32,215 patients. No differences were seen between INT and CONV targets for hospital mortality or ICU mortality. INT targets were associated with lower ICU length of stay (LOS), infections, and critical illness polyneuropathy (CIP); however, INT targets demonstrated a 3.6-fold higher risk of severe hypoglycemia. Most of the studies with significant differences contained serious inconsistencies or risk of bias. In the subgroup analyses, INT targets demonstrated favorable neurologic outcomes in neurologic ICU patients, lower ICU LOS in mixed ICU patients, and lower ICU mortality in the cardiac surgery subgroup. CONCLUSIONS:INT BG targets demonstrated mild to moderate improvements in several important morbidity secondary outcomes, including LOS, infections, and CIP, but were associated with a 3.6-fold higher risk of severe hypoglycemia. No differences were seen in ICU or hospital mortality. INT targets should not be routinely used over CONV targets when trying to minimize hypoglycemia as a marker of patient safety. However, as stated in the Society of Critical Care Medicine guidelines, a lower target within the INT range (110-140 mg/dL; 6.1-7.8 mmol/L) may be considered acceptable in select centers where the risk of hypoglycemia is documented to be negligible based on routine assessment and with the use of optimized glycemic management protocols.
Introduction Chronic spontaneous urticaria (CSU) manifests as hives and/or angioedema lasting ≥6 weeks. Angioedema impacts up to 50% of CSU patients and is associated with complicated management and impaired quality of life. While biologics omalizumab, dupilumab, and oral therapy remibrutinib are approved for CSU treatment, their effects on angioedema remain poorly defined due to inconsistent outcome reporting. This study evaluates angioedema outcomes and reporting gaps across omalizumab, dupilumab, and remibrutinib randomized controlled trials (RCTs). Methods The systematic review (PROSPERO ID: 1218704) was conducted according to PRISMA guidelines. Web of Science, Medline, Embase, and CENTRAL were searched for January 2012 to November 2025 publications. Eligible trials included phase II/III RCTs, human patients, and reported angioedema outcomes. Risk of bias and certainty of evidence were assessed using RoB2 and GRADE. Random-effects meta-analyses were performed. Results Thirteen phase II/III RCTs were included, and angioedema outcome reporting was highly heterogeneous. Baseline AAS7 was reported in 8/13 trials (61.5%), while AE-QoL and AAS7 week 24 were each reported in 1/13 (7.7%). Angioedema-free days and cumulative angioedema-free weeks were reported in 3/13 (23.1%) and 5/13 (38.5%), respectively, and time to recurrence in 4/13 (30.8%).Meta-analysis of three omalizumab trials demonstrated no significant improvement in angioedema-free days (weeks 4-12) versus placebo [300mg:MD=2.60(95%CI:-0.88-6.08);I²=0%], while pooled-dose sensitivity analysis showed significant benefit [pooled:MD=3.36(95%CI:0.36-6.37);I²=0%]. Conclusion Despite growing CSU therapy availability, their true impact on angioedema remains unclear. Angioedema outcome reporting is inconsistent and unstandardized across RCTs, limiting cross-trial comparability. In future trials, standardized and validated angioedema outcome reporting would enable robust characterization, enhancing widespread patient-centered care.